Summary | |
---|---|
Symbol | MPLKIP |
Name | M-phase specific PLK1 interacting protein |
Aliases | ORF20; TTDN1; C7orf11; chromosome 7 open reading frame 11; ABHS; TTD4; Russell-Silver syndrome region; TTD n ...... |
Chromosomal Location | 7p14 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Nucleus. Cytoplasm. Cytoplasm, cytoskeleton, microtubule organizing center, centrosome. Note=The subcellular location is regulated during cell cycle. During interphase located in the nucleus. During mitosis located at the centrosome and dispersed in the cytoplasm. During telophase located in the midbody. Colocalizes with PLK1 at the centrosome in M phase. |
Domain |
PF15502 M-phase-specific PLK1-interacting protein |
Function |
May play a role in maintenance of cell cycle integrity by regulating mitosis or cytokinesis. |
Biological Process |
GO:0007067 mitotic nuclear division |
Molecular Function | - |
Cellular Component |
GO:0005813 centrosome GO:0030496 midbody |
KEGG | - |
Reactome | - |
Summary | |
---|---|
Symbol | MPLKIP |
Name | M-phase specific PLK1 interacting protein |
Aliases | ORF20; TTDN1; C7orf11; chromosome 7 open reading frame 11; ABHS; TTD4; Russell-Silver syndrome region; TTD n ...... |
Chromosomal Location | 7p14 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between MPLKIP and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
There is no record. |
Summary | |
---|---|
Symbol | MPLKIP |
Name | M-phase specific PLK1 interacting protein |
Aliases | ORF20; TTDN1; C7orf11; chromosome 7 open reading frame 11; ABHS; TTD4; Russell-Silver syndrome region; TTD n ...... |
Chromosomal Location | 7p14 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of MPLKIP in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | MPLKIP |
Name | M-phase specific PLK1 interacting protein |
Aliases | ORF20; TTDN1; C7orf11; chromosome 7 open reading frame 11; ABHS; TTD4; Russell-Silver syndrome region; TTD n ...... |
Chromosomal Location | 7p14 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of MPLKIP in various data sets.
|
Points in the above scatter plot represent the mutation difference of MPLKIP in various data sets.
|
Summary | |
---|---|
Symbol | MPLKIP |
Name | M-phase specific PLK1 interacting protein |
Aliases | ORF20; TTDN1; C7orf11; chromosome 7 open reading frame 11; ABHS; TTD4; Russell-Silver syndrome region; TTD n ...... |
Chromosomal Location | 7p14 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of MPLKIP. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | MPLKIP |
Name | M-phase specific PLK1 interacting protein |
Aliases | ORF20; TTDN1; C7orf11; chromosome 7 open reading frame 11; ABHS; TTD4; Russell-Silver syndrome region; TTD n ...... |
Chromosomal Location | 7p14 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of MPLKIP. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by MPLKIP. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | MPLKIP |
Name | M-phase specific PLK1 interacting protein |
Aliases | ORF20; TTDN1; C7orf11; chromosome 7 open reading frame 11; ABHS; TTD4; Russell-Silver syndrome region; TTD n ...... |
Chromosomal Location | 7p14 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of MPLKIP. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | MPLKIP |
Name | M-phase specific PLK1 interacting protein |
Aliases | ORF20; TTDN1; C7orf11; chromosome 7 open reading frame 11; ABHS; TTD4; Russell-Silver syndrome region; TTD n ...... |
Chromosomal Location | 7p14 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of MPLKIP expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | MPLKIP |
Name | M-phase specific PLK1 interacting protein |
Aliases | ORF20; TTDN1; C7orf11; chromosome 7 open reading frame 11; ABHS; TTD4; Russell-Silver syndrome region; TTD n ...... |
Chromosomal Location | 7p14 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between MPLKIP and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | MPLKIP |
Name | M-phase specific PLK1 interacting protein |
Aliases | ORF20; TTDN1; C7orf11; chromosome 7 open reading frame 11; ABHS; TTD4; Russell-Silver syndrome region; TTD n ...... |
Chromosomal Location | 7p14 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting MPLKIP collected from DrugBank database. |
There is no record. |